Brought to you by 
Strides Arcolab divests generic injectables unit Agila to Mylan for $1.75bn
26 Aug 2020
Executive Summary
In its largest acquisition since buying Merck KGAA’s generics business for $6.7bn in 2007, Mylan Inc. is taking over Agila Specialties Pvt. Ltd. from Indian drug company Strides Arcolab Ltd. for $1.6bn in cash up front plus $250mm in earn-outs. The transaction also includes affiliate Agila Specialties Asia Pte. Ltd. Singapore. Mylan will not be assuming any Agila debt.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
Deal Status
- Final
Deal Type
-
Acquisition
- Divestiture/Spin-Out
- Full Acquisition
- Includes Contract
- Includes Earnout
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Strides Arcolab divests generic injectables unit Agila to Mylan for $1.75bn
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice